CN103429269B - 含有与聚阴离子多肽偶联的、衍生自cd4受体的肽的用于治疗艾滋病的共轭分子 - Google Patents

含有与聚阴离子多肽偶联的、衍生自cd4受体的肽的用于治疗艾滋病的共轭分子 Download PDF

Info

Publication number
CN103429269B
CN103429269B CN201280013736.1A CN201280013736A CN103429269B CN 103429269 B CN103429269 B CN 103429269B CN 201280013736 A CN201280013736 A CN 201280013736A CN 103429269 B CN103429269 B CN 103429269B
Authority
CN
China
Prior art keywords
group
peptide
xaa
acid
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280013736.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103429269A (zh
Inventor
F·巴勒斯克
H·洛尔塔雅各布
D·博纳夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Universite Paris Sud
Institut Pasteur
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Universite Paris Sud
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH, Universite Paris Sud, Institut Pasteur filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN103429269A publication Critical patent/CN103429269A/zh
Application granted granted Critical
Publication of CN103429269B publication Critical patent/CN103429269B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201280013736.1A 2011-03-18 2012-03-16 含有与聚阴离子多肽偶联的、衍生自cd4受体的肽的用于治疗艾滋病的共轭分子 Expired - Fee Related CN103429269B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11305309.4 2011-03-18
EP11305309A EP2505210A1 (en) 2011-03-18 2011-03-18 Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanionic polypeptide for the treatment of aids
US201261590992P 2012-01-26 2012-01-26
US61/590,992 2012-01-26
PCT/EP2012/054674 WO2012126833A1 (en) 2011-03-18 2012-03-16 New conjugated molecules comprising a peptide derived from the cd4 receptor coupled to a polyanionic polypeptide for the treatment of aids

Publications (2)

Publication Number Publication Date
CN103429269A CN103429269A (zh) 2013-12-04
CN103429269B true CN103429269B (zh) 2016-05-11

Family

ID=44118425

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280013736.1A Expired - Fee Related CN103429269B (zh) 2011-03-18 2012-03-16 含有与聚阴离子多肽偶联的、衍生自cd4受体的肽的用于治疗艾滋病的共轭分子

Country Status (9)

Country Link
US (1) US9078928B2 (enExample)
EP (2) EP2505210A1 (enExample)
JP (1) JP6046060B2 (enExample)
CN (1) CN103429269B (enExample)
BR (1) BR112013023859A2 (enExample)
CA (1) CA2830012C (enExample)
MX (1) MX336727B (enExample)
WO (1) WO2012126833A1 (enExample)
ZA (1) ZA201306956B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062854A1 (en) * 2014-10-24 2016-04-28 Institut Pasteur Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids
WO2017184564A1 (en) * 2016-04-18 2017-10-26 Icagen, Inc. Sensors and sensor arrays for detection of analytes
US11014961B2 (en) 2017-01-25 2021-05-25 Massachusetts Institute Of Technology Self-labeling miniproteins and conjugates comprising them
CN109081789B (zh) * 2017-06-13 2021-01-01 首都医科大学 氨基正己酰氨基甲环酰氨基正己酰脂肪氨基酸，其合成，活性和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2087911A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS
CN101516909A (zh) * 2006-08-04 2009-08-26 巴斯德研究所 Cd4受体衍生肽及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002338600A (ja) * 2001-05-17 2002-11-27 Japan Science & Technology Corp Ｈｉｖ−１の感染を抑制するポリペプチド
RU2270690C1 (ru) * 2004-06-11 2006-02-27 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") Комплексное анти-вич соединение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516909A (zh) * 2006-08-04 2009-08-26 巴斯德研究所 Cd4受体衍生肽及其制备方法
EP2087911A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS

Also Published As

Publication number Publication date
JP6046060B2 (ja) 2016-12-14
JP2014509604A (ja) 2014-04-21
WO2012126833A1 (en) 2012-09-27
EP2686019B1 (en) 2017-03-01
MX2013010688A (es) 2014-03-27
MX336727B (es) 2016-01-27
EP2505210A1 (en) 2012-10-03
US9078928B2 (en) 2015-07-14
CA2830012C (en) 2018-11-06
EP2686019A1 (en) 2014-01-22
US20140107043A1 (en) 2014-04-17
CA2830012A1 (en) 2012-09-27
ZA201306956B (en) 2014-05-28
BR112013023859A2 (pt) 2018-09-25
CN103429269A (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
US20240209026A1 (en) A4b7 thioether peptide dimer antagonists
WO2021167107A1 (ja) ヒトトランスフェリンレセプター結合ペプチド
CN103429269B (zh) 含有与聚阴离子多肽偶联的、衍生自cd4受体的肽的用于治疗艾滋病的共轭分子
US20240366775A1 (en) Human transferrin receptor binding antibody-peptide conjugate
Wan et al. Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages
JPWO2017217545A1 (ja) プレキシンの結合調節剤
JP6647207B2 (ja) ヘマグルチニン結合ペプチド
US9907860B2 (en) Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to an anionic polypeptide for the treatment of AIDS
US10738083B2 (en) Influenza virus neutralizing peptidomimetic compounds
EA039991B1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160511

Termination date: 20210316